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A B S T R A C T
The ﬁnding of diabetes in association with a pancreatic neuroendocrine tumor (PNET) in patients is un-
common. Here, we describe a 74-year-old diabetes patient with a tumor in the pancreatic head. Calciﬁcation
in the central part of the tumor and signiﬁcant expansion of the pancreatic duct were also detected. In
addition, the patient had a gallstone, which was surgically resected. During surgery, the pancreatic tumor
was biopsied. DNA was extracted from peripheral leukocytes, and MEN1 was excluded by direct se-
quencing of theMEN1 gene. After biochemical and immunohistochemical analyses, a pancreatic somatostatin
tumor was diagnosed.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Background
Pancreatic neuroendocrine tumor (PNET) is an uncommon neo-
plasmwith an incidence of 2.2/1,000,000 [1]. PNET accounts for 1–2%
of all pancreatic tumors [2–4], including nonfunctional tumors and
functional tumors such as insulinoma, gastrinoma, glucagonoma,
vasoactive intestinal polypeptidoma (VIPoma) and somatostatinoma
[5]. Most pancreatic tumors are nonfunctional, and themost common
functional tumor is insulinoma [6].
Somatostatinoma is a rare type of functional PNET that usually
arises in the pancreas and duodenum. The clinical manifestations
of somatostatinoma syndrome include diabetes mellitus, steator-
rhea, and cholelithiasis, which results from the inhibition of
somatostatin [7]. The diagnosis is based on histological and immu-
nohistochemical analyses and particularly on the presence of plasma
somatostatin.
Here, we report a case of a nonfunctional pancreatic
somatostatinoma diagnosed according to the serum somatostatin
level and immunohistochemical staining of a biopsy specimen.
Case report
A 74-year-old male with a ten-year history of diabetes was re-
ferred to our hospital because of a pancreatic head tumor. Premixed
insulin was used to control his blood glucose level. In 2006, he was
found to have a pancreatic head tumor without obvious com-
plaints. Abdominal CT scan revealed an inhomogeneous and well-
marginated tumor with dimensions of 54 × 44 mm in the head of
the pancreas. Calciﬁcation was detected in the central part of the
tumor, and signiﬁcant expansion of the pancreatic duct was ob-
served (Figure1A, B). In 2008, thepatientunderwent cholecystectomy
with commonbile duct incisionbecauseof gallstones.During surgery,
the pancreatic tumorwas also biopsied. The histopathological results
revealed that the tumorwaspositive for creatinekinase (CK), vimentin
(Vim), chromograninA (CHGA), neuron-speciﬁc enolase (NSE), CD34,
andKi67, andnegative for epithelialmembrane antigen (EMA), S100,
smoothmuscle actin (SMA), and AB/PAS. Lightmicroscopy analysis
showed that the tumor cells were arranged in groups or cords and
that the cells were rich in cytoplasm. Based on these results, the
tumor was considered to be a PNET. The patient refused surgical
treatment, and follow-up observation was continued.
When the patient arrived at our hospital, physical examination re-
vealed no enlargement of the superﬁcial lymph nodes. The levels of
serum tumor markers, including carcinoembryonic antigen (CEA),
α-fetoprotein (AFP), CA125, CA199, prostate-speciﬁc antigen (PSA), and
fPSA, and the fPSA/tPSA ratio were within the normal ranges.
Glycosylated hemoglobinwas 8.9% (4.7–6.3%), and fasting insulin was
165.40 μIU/ml (2.6–24.9μIU/ml). Furthermore, hormonal evaluation re-
vealed an aldosterone level of 124.78 pg/ml, serum cortisol level of
166.51 ng/ml (66–286 ng/ml), glucagon level of 155.77 pg/ml (0–
200 pg/ml), adrenocorticotropic hormone (ACTH) level of 18.0 pg/ml
(0–46 pg/ml) and somatostatin level of 1.492 ng/ml (<0.1 ng/ml). Thus,
we also performed immunohistochemical analysis of the biopsy. The
biopsy was positive for somatostatin and glucagon (Figure 1C, D) and
negative for insulin and pro-insulin (data not shown). DNA was ex-
tracted from peripheral leukocytes, and primers were designed to
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amplify allMEN1 exons. The PCRproductswere directly sequencedwith
an ABI 3730Genetic Analyzer (Applied Biosystems, Foster City, CA). Se-
quence analysis revealed that nomutationswere present in theMEN1
gene. After a detailed review of the biochemical, CT scan and immu-
nohistochemical results, the tumorwasdiagnosedas a somatostatinoma.
Abdominal CT scan was performed every 6 months, and no dynamic
changes in the tumorwere observed. At 4 years of follow-up, the patient
was without any complaints.
Discussion
Speciﬁc types of diabetes include diseases of the exocrine pan-
creas and endocrinopathies [8]. The patient in the present case had
diabetes prior to the discovery of a pancreatic tumor in 2006. Based
on the tumor size and calciﬁcation, we deduced that the tumor had
been present for a relatively long period of time. Thus, the diabe-
tes may have been associated with the pancreatic somatostatinoma.
The tumor may have been associated with the diabetes by both re-
ducing the beta cell mass and inhibiting insulin secretion.
The estimated annual incidence of somatostatinoma is 1 in
4,000,000 individuals [9]. Approximately 68% of cases originate in
the pancreas, in addition to 19% in the duodenum and 3% in both
the ampulla of Vater and small intestine [10]. In 1977, Larsson et al.
[11] ﬁrst described pancreatic somatostatinoma. Since then, only
approximately 80 cases have been reported [12]. Excessive secre-
tion of somatostatin by the somatostatinoma can result in the clinical
manifestations of cholelithiasis, diarrhea, steatorrhea and diabe-
tes, known as somatostatinoma syndrome [11]. Some somatostatin
tumors secrete a variety of hormones, such as gastrin, insulin, adrenal
cortical hormone, calcitonin, glucagon and vasoactive peptides.
However, the clinical manifestations tend to be caused by a par-
ticular hormone [13].
Only20%of patientswitha somatostatinomaexhibit typical symp-
toms [14]. Most patients are asymptomatic or have nonspeciﬁc
symptoms causedby the localmass effect,whichmakes these tumors
diﬃcult to diagnose [15]. Both Tomono et al. [14] and Mori et al.
[12] have reported asymptomatic patients with pancreatic masses
thatwereultimatelydiagnosedaspancreatic somatostatinomas. Thus,
endoscopic ultrasound-guided ﬁne needle aspiration (EUS-FNA) and
immunohistochemical staining are useful in the preoperative di-
agnosis of pancreatic somatostatinoma [12].
Multiple endocrine neoplasia type 1, caused by MEN1 gene mu-
tations, may also lead to development of pancreaticmasses. However,
no mutation was detected in any of the exons of the MEN1 gene in
our patient. His pancreatic cancer was mainly located in the head
of the pancreas and accounted for approximately 70% of the pan-
creatic mass. Abdominal CT scan performed in 2006 revealed the
presence of a pancreatic mass. However, because of the longer du-
ration and lack of clinical manifestations, such as abdominal pain,
jaundice and weight loss, and the normal tumor marker levels, a
diagnosis of pancreatic cancer was unlikely. The patient denied a
history of acute pancreatitis or abdominal trauma, which did not
support a diagnosis of pancreatic pseudocyst.
We preliminarily believed that tumor was a PNET. Further anal-
ysis indicated that the tumor was negative for insulin and C-peptide
and was positive for glucagon and somatostatin, based on the im-
munohistochemistry results. Hormone analysis indicated that the
patient’s somatostatin level was signiﬁcantly elevated (1.492 ng/
ml), which conﬁrmed the diagnosis. PNET is considered more
indolent than adenocarcinoma of the pancreas; thus, it has a better
prognosis [4]. This patient refused surgical treatment, and follow-
up observation was continued. However, pancreaticoduodenectomy
is the most commonly performed operation for somatostatinoma
in the pancreatic head.
In conclusion, we have described a diabetes patient with a PNET
that was demonstrated to be a somatostatinoma. We have also dis-
cussed the pathogenesis of this tumor.
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